secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001104659-26-002306
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia reports preliminary 2025 YUTREPIA net sales of $148.3M; Q4 sales $90.1M
--------------------------------------------------------------------------------

- Q4 2025 YUTREPIA net sales ~$90.1M; full-year 2025 net sales ~$148.3M, up 74% QoQ.
- Over 2,800 unique patient prescriptions since June 2025 launch; 85% conversion rate (Nov 2025).
- Generated >$30M positive cash flow in Q4 2025; cash and equivalents ~$190.7M as of Dec 31.
- Plan to expand field sales team in 2026; initiated multiple clinical studies for YUTREPIA and L606.
- Preliminary results to be followed by audited full-year financials in Feb 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926002306/0001104659-26-002306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465926002306/tm262716d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer